Symbols / ADIL Stock $1.69 -2.31% Adial Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
ADIL (Stock) Chart
About

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 2.41M
Enterprise Value -3.47M Income -7.98M Sales —
Book/sh 4.75 Cash/sh 4.12 Dividend Yield —
Payout 0.00% Employees 5 IPO —
P/E — Forward P/E -0.35 PEG —
P/S — P/B 0.36 P/C —
EV/EBITDA 0.45 EV/Sales — Quick Ratio 4.21
Current Ratio 4.42 Debt/Eq — LT Debt/Eq —
EPS (ttm) -11.93 EPS next Y -4.79 EPS Growth —
Revenue Growth — Earnings 2026-03-05 17:00 ROA -83.20%
ROE -170.73% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 1.43M
Shs Float 1.31M Short Float 5.62% Short Ratio 0.50
Short Interest — 52W High 30.25 52W Low 1.54
Beta 1.40 Avg Volume 85.49K Volume 48.58K
Target Price $23.33 Recom None Prev Close $1.73
Price $1.69 Change -2.31%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$23.33
Mean price target
2. Current target
$1.69
Latest analyst target
3. DCF / Fair value
$-47.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.69
Low
$8.00
High
$42.00
Mean
$23.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-30 up Maxim Group Hold → Buy $2
2024-11-14 init Rodman & Renshaw — → Buy $8
News
RSS: Latest ADIL news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
7.80
-5.85%
8.28
+20.27%
6.89
-36.57%
10.86
Research And Development
2.62
-18.88%
3.23
+154.86%
1.27
-35.03%
1.95
Selling General And Administration
5.18
+2.46%
5.06
-10.06%
5.62
-36.91%
8.91
General And Administrative Expense
5.18
+2.46%
5.06
-10.06%
5.62
-36.91%
8.91
Other Gand A
5.18
+2.46%
5.06
-10.06%
5.62
-36.91%
8.91
Total Expenses
7.80
-5.85%
8.28
+20.27%
6.89
-36.57%
10.86
Operating Income
-7.80
+5.85%
-8.28
-20.27%
-6.89
+36.57%
-10.86
Total Operating Income As Reported
-7.80
+5.85%
-8.28
-20.27%
-6.89
+36.57%
-10.86
EBITDA
-7.80
+5.85%
-8.28
-20.28%
-6.89
+36.57%
-10.86
Normalized EBITDA
-7.80
-104.19%
-3.82
+44.54%
-6.89
+36.57%
-10.86
Reconciled Depreciation
0.00
+0.00%
0.00
+0.18%
0.00
+0.00%
0.00
EBIT
-7.80
+5.85%
-8.28
-20.27%
-6.89
+36.57%
-10.86
Total Unusual Items
0.00
+100.00%
-4.46
0.00
-100.00%
0.52
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-4.46
0.00
-100.00%
0.52
Special Income Charges
0.00
+100.00%
-4.46
0.00
-100.00%
0.52
Other Special Charges
—
4.46
—
—
Impairment Of Capital Assets
—
—
—
—
Restructuring And Mergern Acquisition
—
—
—
-0.52
Write Off
—
—
—
0.00
Net Income
-7.98
+39.56%
-13.20
-157.59%
-5.12
+59.76%
-12.73
Pretax Income
-7.98
+39.56%
-13.20
-88.48%
-7.00
+35.14%
-10.80
Net Non Operating Interest Income Expense
0.15
-16.28%
0.18
+156.04%
0.07
+10.17%
0.06
Net Interest Income
0.15
-16.28%
0.18
+156.04%
0.07
+10.17%
0.06
Interest Income Non Operating
0.15
-16.28%
0.18
+156.04%
0.07
+10.17%
0.06
Interest Income
0.15
-16.28%
0.18
+156.04%
0.07
+10.17%
0.06
Other Income Expense
-0.33
+93.57%
-5.09
-2671.39%
-0.18
-135.20%
0.52
Other Non Operating Income Expenses
0.16
+319.68%
-0.08
-838.47%
0.01
—
Tax Provision
—
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-7.98
+39.56%
-13.20
-157.59%
-5.12
+59.76%
-12.73
Net Income From Continuing Operation Net Minority Interest
-7.98
+39.56%
-13.20
-88.48%
-7.00
+35.14%
-10.80
Net Income From Continuing And Discontinued Operation
-7.98
+39.56%
-13.20
-157.59%
-5.12
+59.76%
-12.73
Net Income Continuous Operations
-7.98
+39.56%
-13.20
-88.48%
-7.00
+35.14%
-10.80
Net Income Discontinuous Operations
—
0.00
-100.00%
1.88
+197.07%
-1.94
Normalized Income
-7.98
+8.66%
-8.73
-24.72%
-7.00
+35.14%
-10.80
Net Income Common Stockholders
-7.98
+39.56%
-13.20
-157.59%
-5.12
+59.76%
-12.73
Diluted EPS
—
-68.01
+24.43%
-90.00
+71.68%
-317.75
Basic EPS
—
-68.01
+24.43%
-90.00
+71.68%
-317.75
Basic Average Shares
—
0.19
+240.54%
0.06
+42.25%
0.04
Diluted Average Shares
—
0.19
+240.54%
0.06
+42.25%
0.04
Diluted NI Availto Com Stockholders
-7.98
+39.56%
-13.20
-157.59%
-5.12
+59.76%
-12.73
Earnings From Equity Interest
-0.49
+10.88%
-0.55
-184.80%
-0.19
0.00
Line Item Trend 2023-12-31
Total Assets
4.74
Current Assets
3.20
Cash Cash Equivalents And Short Term Investments
2.83
Cash And Cash Equivalents
2.83
Prepaid Assets
—
Assets Held For Sale Current
0.00
Other Current Assets
0.37
Total Non Current Assets
1.54
Net PPE
—
Gross PPE
—
Properties
—
Buildings And Improvements
—
Other Properties
—
Goodwill And Other Intangible Assets
0.00
Goodwill
—
Other Intangible Assets
0.00
Investments And Advances
1.53
Long Term Equity Investment
1.53
Non Current Prepaid Assets
—
Other Non Current Assets
—
Total Liabilities Net Minority Interest
0.65
Current Liabilities
0.65
Payables And Accrued Expenses
0.23
Payables
0.13
Accounts Payable
0.10
Current Accrued Expenses
0.10
Pensionand Other Post Retirement Benefit Plans Current
0.42
Current Debt And Capital Lease Obligation
—
Current Capital Lease Obligation
—
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
0.00
Liabilities Heldfor Sale Non Current
0.00
Long Term Debt And Capital Lease Obligation
—
Long Term Capital Lease Obligation
—
Non Current Deferred Liabilities
—
Non Current Deferred Taxes Liabilities
—
Other Non Current Liabilities
—
Stockholders Equity
4.08
Common Stock Equity
4.08
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.07
Ordinary Shares Number
0.07
Treasury Shares Number
0.00
Additional Paid In Capital
72.88
Retained Earnings
-68.80
Total Equity Gross Minority Interest
4.08
Total Capitalization
4.08
Working Capital
2.55
Invested Capital
4.08
Total Debt
—
Capital Lease Obligations
—
Net Tangible Assets
4.08
Tangible Book Value
4.08
Dueto Related Parties Current
0.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-6.49
+6.21%
-6.92
-1.70%
-6.81
+39.15%
-11.19
Cash Flow From Continuing Operating Activities
-6.49
+6.21%
-6.92
-19.28%
-5.80
+32.47%
-8.59
Cash From Discontinued Operating Activities
—
—
-1.00
+61.29%
-2.59
Net Income From Continuing Operations
-7.98
+39.56%
-13.20
-88.48%
-7.00
+35.14%
-10.80
Depreciation Amortization Depletion
0.00
+0.00%
0.00
+0.18%
0.00
+0.00%
0.00
Depreciation
—
—
—
0.06
Amortization Cash Flow
0.00
+0.00%
0.00
+0.18%
0.00
+0.00%
0.00
Depreciation And Amortization
0.00
+0.00%
0.00
+0.18%
0.00
+0.00%
0.00
Amortization Of Intangibles
0.00
+0.00%
0.00
+0.18%
0.00
+0.00%
0.00
Other Non Cash Items
-0.15
-103.30%
4.54
+8646.32%
0.05
+109.94%
-0.52
Stock Based Compensation
0.68
-15.14%
0.80
-54.37%
1.75
-48.25%
3.37
Asset Impairment Charge
—
—
—
0.00
Deferred Tax
—
—
—
-0.00
Deferred Income Tax
—
—
—
-0.00
Operating Gains Losses
0.49
-10.88%
0.55
+184.80%
0.19
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
0.47
+20.60%
0.39
+148.62%
-0.79
+32.28%
-1.17
Change In Prepaid Assets
0.01
-86.47%
0.06
+385.96%
-0.02
-144.32%
0.05
Change In Payables And Accrued Expense
0.46
+41.61%
0.32
+141.81%
-0.77
+36.86%
-1.22
Change In Accrued Expense
0.10
-33.91%
0.15
+124.77%
-0.61
+50.54%
-1.24
Change In Payable
0.36
+108.64%
0.17
+207.28%
-0.16
-1107.27%
0.02
Change In Account Payable
0.36
+108.64%
0.17
+207.28%
-0.16
-1107.27%
0.02
Change In Other Current Liabilities
—
—
—
-0.05
Investing Cash Flow
0.15
0.00
-100.00%
1.50
0.00
Cash Flow From Continuing Investing Activities
0.15
0.00
-100.00%
1.50
0.00
Net PPE Purchase And Sale
—
—
—
0.00
Purchase Of PPE
—
—
—
0.00
Capital Expenditure
—
—
—
—
Net Business Purchase And Sale
0.15
0.00
—
0.00
Net Other Investing Changes
—
—
1.50
—
Financing Cash Flow
8.47
+8.00%
7.85
+89.87%
4.13
-54.72%
9.13
Cash Flow From Continuing Financing Activities
8.47
+8.00%
7.85
+89.87%
4.13
-54.72%
9.13
Net Common Stock Issuance
3.66
-9.02%
4.02
+436.24%
0.75
-91.78%
9.12
Proceeds From Stock Option Exercised
4.81
+25.90%
3.82
+13.02%
3.38
+181337.80%
0.00
Net Other Financing Charges
—
—
-0.00
—
Changes In Cash
2.13
+130.73%
0.92
+178.61%
-1.17
+42.99%
-2.06
Beginning Cash Position
3.75
+32.66%
2.83
-29.35%
4.00
-33.99%
6.06
End Cash Position
5.88
+56.81%
3.75
+32.66%
2.83
-29.35%
4.00
Free Cash Flow
-6.49
+6.21%
-6.92
-1.70%
-6.81
+39.15%
-11.19
Interest Paid Supplemental Data
—
0.00
0.00
0.00
Income Tax Paid Supplemental Data
—
0.00
0.00
0.00
Common Stock Issuance
3.66
-9.02%
4.02
+436.24%
0.75
-91.78%
9.12
Earnings Losses From Equity Investments
0.49
-10.88%
0.55
+184.80%
0.19
0.00
Issuance Of Capital Stock
3.66
-9.02%
4.02
+436.24%
0.75
-91.78%
9.12
Sale Of Business
0.15
0.00
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category